Two new corporate affairs leads appointed at Pfizer
pharmafile | December 9, 2015 | Appointment | Medical Communications | Pfizer, corporate affairs
Pfizer has appointed MacKay Jimeson and Niesha Foster as corporate affairs leads.
The company recently restructured its global pharma business into four categories: cardiovascular metabolic disease, inflammation and immunology, rare disease and neuroscience and pain.
As part of the new organisational structure, Jimeson is corporate affairs leader for the cardiovascular metabolic disease, neuroscience and pain businesses, while Foster is corporate affairs head for the company’s inflammation and immunology and rare disease businesses.
Both are responsible for delivering integrated strategies for their respective categories. Jimeson will assume global responsibility for public policy, government affairs, communications and CSR, and will also work with the business presidents on market development and establishing Pfizer’s reputation as a leader in these categories around the world.
Jimeson has worked for Pfizer since 2009, when he joined as spokesperson and director of media relations. Before Pfizer, Jimeson was public affairs director for WRScompass, an environmental company, and was also a communications aide on Republican Senator John McCain’s 2008 US presidential campaign, and press secretary for then Florida Governor Jeb Bush between 2001 and 2005.
“It has been a great six-year run at Pfizer, and I’m very happy the company continues to present new opportunities to grow,” Jimeson says.
Foster has worked at Pfizer since 2003. She currently serves as chief of staff for worldwide research and development where she manages day-to-day activities related to R&D, and was previously served as chief of staff for worldwide policy. Before joining Pfizer, Foster was a senior manager at the National Football League and worked in audit at Pricewaterhouse.
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
